.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This phase 2 randomized, double-blind, placebo-controlled trial evaluated vemircopan, an oral selective factor D inhibitor that blocks alternative-pathway complement activation, in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis. The study was conducted at 60 sites across eight countries. Seventy participants were randomized to vemircopan 180 mg twice daily (n = 28), vemircopan 120 mg twice daily (n = 14), or placebo (n = 28), with an eight-week primary evaluation period. The primary endpoint was a reduction of at least two points in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score sustained for four consecutive weeks without rescue therapy. The endpoint was achieved by 16/28 participants (57%) receiving 180 mg, 8/14 (57%) receiving 120 mg, and 18/28 (64%) receiving placebo. Neither dose showed a statistically significant benefit over placebo, and no significant differences were observed in secondary efficacy outcomes. No meningococcal infections were reported; however, one participant died from hepatic failure and another discontinued treatment because of herpes simplex meningitis. The study was terminated because the prespecified minimum efficacy threshold was not met. Conclusion: Vemircopan did not demonstrate sufficient efficacy in this trial to support further development under the study’s original criteria. The results highlight the need for additional research before alternative-pathway complement inhibition can be considered an effective treatment strategy for this form of myasthenia gravis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This phase 2 randomized, double-blind, placebo-controlled trial evaluated vemircopan, an oral selective factor D inhibitor that blocks alternative-pathway complement activation, in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis. The study was conducted at 60 sites across eight countries. Seventy participants were randomized to vemircopan 180 mg twice daily (n = 28), vemircopan 120 mg twice daily (n = 14), or placebo (n = 28), with an eight-week primary evaluation period. The primary endpoint was a reduction of at least two points in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score sustained for four consecutive weeks without rescue therapy. The endpoint was achieved by 16/28 participants (57%) receiving 180 mg, 8/14 (57%) receiving 120 mg, and 18/28 (64%) receiving placebo. Neither dose showed a statistically significant benefit over placebo, and no significant differences were observed in secondary efficacy outcomes. No meningococcal infections were reported; however, one participant died from hepatic failure and another discontinued treatment because of herpes simplex meningitis. The study was terminated because the prespecified minimum efficacy threshold was not met. Conclusion: Vemircopan did not demonstrate sufficient efficacy in this trial to support further development under the study’s original criteria. The results highlight the need for additional research before alternative-pathway complement inhibition can be considered an effective treatment strategy for this form of myasthenia gravis.
Today
Good's syndrome links thymoma with severe humoral and cellular immunodeficiency. While autoantibodies against cytokines like IL-12 and interferons drive pathology, early diagnosis and prompt immunoglobulin replacement therapy have elevated 20-year survival rates above 60%.
Today
A KGMU study reveals over half of women with breast abnormalities fail to undergo diagnostic confirmation, leading to advanced-stage detection. Discover the socio-cultural barriers, clinical risks of incomplete resection, and community-level solutions needed to bridge the critical screening-to-diagnosis gap in India.
Today
A meta-analysis of 18 studies reveals that bariatric surgery does not significantly alter circulating homocysteine levels, regardless of follow-up duration. Clinicians must maintain vigilance over post-surgical micronutrient supplementation to prevent hyperhomocysteinemia.
Today
Researchers have engineered a self-powered Zn/C micro-galvanic electrospun membrane that couples sustained zinc release with endogenous microcurrents. This bioelectric scaffold stimulates M2 macrophage polarization and accelerates bone deposition to achieve robust cranial defect regeneration.
Today
A nationwide UK Cystic Fibrosis Registry study demonstrates that higher updated mean HbA1c levels correlate with a graded, significant increase in all-cause mortality among individuals with cystic fibrosis-related diabetes, reinforcing the critical need for proactive glycemic monitoring and intervention.
Today
